literature

HIV mutation literature information.

Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

PMID: 26850643 2016 Nucleic acids research

Result: The P236L mutation characteristic for delavirdine (DLV) resistance is absent in MR-RT (http://hivdb.stanford.edu/).

The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.

PMID: 25926857 2014 AIDS research and therapy

Discussion: The rank of fitness among mutant viruses was as follows: wild type (WT) >= Y181C >= K103N >= G190A >= V106A >= P236L >= G190S.

The prevalence of transmitted HIV drug resistance among MSM in Anhui province, China.

PMID: 25035709 2014 AIDS research and therapy

Result: T69A/N/S, V179E and P236L were polymorphism mutations against RTIs.

Discussion: For example, L10V, V11I/V, L33F, T69A/N/S, and P236L were present only in individuals with CRF01_AE strains.

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

PMID: 20102272 2010 The Journal of infectious diseases

Method: For single-genome sequencing analyses, a total of 27 subjects (15 NNRTI-naive and 12 NNRTI-experienced) were randomly selected from enrollees meeting the following criteria: i) entry sample negative for NNRTI-resistance mutations by standard genotype analysis (ViroSeq platform; Celera, Alameda, CA); ii) reached a protocol-defined virologic failure endpoint by study week 24, and iii) the virologic failure sample had one or more major NNRTI-resistance mutations (L100I, K101E, K103N, V106A or M, V108I, Y181C or I, Y188C, H, or L, G

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

PMID: 20805392 2010 Antimicrobial agents and chemotherapy

Abstract: In subtype B viruses, on the other hand, known NNRTI-associated mutations (e.g., Y181C, P236L, L100I, V179D, and K103N) were selected by the NNRTIs.

Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

PMID: 20592075 2010 Journal of virology

Abstract: K103N and Y181C mutants had normal RNase H activity; V106A, G190A, and G190S mutants had moderate reductions in activity; and the P236L mutant had substantially reduced activity.

Abstract: K103N and Y181C viruses had fitness similar to that of the wild type while V106A, G190A, G190S, and P236L viruses had reduced fitness.

Abstract: In conclusion, severe defects in RNase H activity alone, exemplified by the P236L mutant, appear sufficient to cause a substantial reduction in fitness.

Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

PMID: 20535242 2010 Letters in drug design & discovery

Introduction: Mutations associated with resistance to NNRTIs include L100I, K101E, K103N, V106A, V108I, V179D, Y181C, Y188C/L/H, G190A/E/S, M230L, P236L and Y318F.

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

PMID: 20462946 2010 The Journal of antimicrobial chemotherapy

Method: These mutations included: (i) 46 non-polymorphic NNRTI-selected mutations at 28 positions (I94L, A98G, L100I, K101E/H/N/P, K102N, K103H/N/S/T, S105T, V106A/M, E138Q, T139R, I178F, V179F, Y181C/I/V, Y188C/H/L, G190A/C/E/Q/S, H221C/Y, K223T,

PMID: 20219553 2010 Antiviral research

Abstract: Two pathways to loss of susceptibility to RO-0335 were observed, containing patterns of amino acid changes at either V106I/A plus F227C (with additional contributions from A98G, V108I, E138K, M230L and P236L) or V106I/Y188L (with a potential contribution from L100I, E138K and Y181C).

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

PMID: 19320243 2009 Antiviral therapy

Abstract: These included V90I, A98G, L100I, K1O1E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F

Browser Board

Co-occurred Entities

Filtrator